G1 Therapeutics, Inc. (GTHX)
NASDAQ: GTHX · IEX Real-Time Price · USD
4.320
-0.150 (-3.36%)
At close: Mar 28, 2024, 4:00 PM
4.410
+0.090 (2.08%)
After-hours: Mar 28, 2024, 7:59 PM EDT

G1 Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 202320222021202020192018201720162015
Revenue
82.5151.331.4845.2900000.52
Revenue Growth (YoY)
60.84%62.98%-30.49%------
Cost of Revenue
7.23.752.02000000
Gross Profit
75.3247.5529.4645.2900000.52
Selling, General & Admin
71.13100.4295.6968.4940.0418.67.095.233.22
Research & Development
43.7183.3276.2373.278970.6853.8825.1612.73
Operating Expenses
114.84183.73171.92141.76129.0489.2960.9730.3915.95
Operating Income
-39.53-136.18-142.46-96.48-129.04-89.29-60.97-30.39-15.42
Interest Expense / Income
10.0410.434.671.7800000
Other Expense / Income
-4.71-0.750.3-0.41-6.59-4-0.85-0.14.84
Pretax Income
-44.85-145.86-147.43-97.84-122.45-85.29-60.12-30.29-20.26
Income Tax
3.121.70.931.4100000
Net Income
-47.97-147.56-148.35-99.25-122.45-85.29-60.12-30.29-20.26
Preferred Dividends
0000004.764.411.43
Net Income Common
-47.97-147.56-148.35-99.25-122.45-85.29-64.88-34.7-21.69
Shares Outstanding (Basic)
5244423837331811
Shares Outstanding (Diluted)
5244423837331811
Shares Change
18.58%4.01%10.73%1.01%12.55%83.08%1123.82%10.59%-
EPS (Basic)
-0.93-3.38-3.54-2.62-3.27-2.56-3.57-23.33-16.13
EPS (Diluted)
-0.93-3.38-3.54-2.62-3.27-2.56-3.57-23.33-16.13
Free Cash Flow
-38.34-129.13-132.11-83.59-102.29-75.02-50.81-25.39-13.93
Free Cash Flow Per Share
-0.74-2.96-3.15-2.21-2.73-2.25-2.79-17.07-10.36
Gross Margin
91.28%92.69%93.60%100.00%----100.00%
Operating Margin
-47.91%-265.45%-452.59%-213.04%-----2954.79%
Profit Margin
-58.13%-287.63%-471.32%-219.18%-----4155.17%
Free Cash Flow Margin
-46.46%-251.70%-419.71%-184.59%-----2668.97%
EBITDA
-34.3-134.9-142.29-95.48-122.09-85.11-60.03-30.22-20.22
EBITDA Margin
-41.57%-262.95%-452.06%-210.85%-----3873.75%
Depreciation & Amortization
0.510.530.470.580.360.180.090.070.04
EBIT
-34.81-135.43-142.76-96.07-122.45-85.29-60.12-30.29-20.26
EBIT Margin
-42.19%-263.99%-453.55%-212.14%-----3881.80%
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).